Food and Drug Administration approved LIBTAYO® (cemiplimab-rwlc)  (Regeneron Pharmaceuticals, Inc.) in combination with platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations.  Read More. 

Please see additional Important Safety Information below and the full LIBTAYO Prescribing Information here or go to www.libtayohcp.com.